N-(4-hydroxynaphthalen-1-yl)acetamide | 85-12-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(4-hydroxynaphthalen-1-yl)acetamide
• CAS: 85-12-1
• 化学式: C₁₂H₁₁NO₂
• mdl: MFCD02077597
• 分子量: 201.225
• InChiKey: KBJFWKRDRSFIBS-UHFFFAOYSA-N

物化性质

• 沸点：
  486.1±28.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)
• 熔点：
  178 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(4-hydroxynaphthalen-1-yl)acetamide 在 盐酸 、 sodium hydroxide 作用下， 生成 (4-amino-[1]naphthyloxy)-acetic acid
  参考文献：
  名称：

  Jacobs; Heidelberger, Journal of the American Chemical Society, 1917, vol. 39, p. 2190

  摘要：

  DOI：
• 作为产物：
  描述：

  1-氨基-4-硝基萘 在 镍 sodium hydroxide 、 氢气 作用下， 以 甲醇 为溶剂， 反应 18.17h， 生成 N-(4-hydroxynaphthalen-1-yl)acetamide
  参考文献：
  名称：

  Antimalarial drugs. 61. Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-alkylphenols and their N.omega.-oxides

  摘要：

  A series of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-alkylphenols and their N omega-oxides were synthesized by the condensation of 4,7-dichloroquinoline and 4,7-dichloroquinoline N omega-oxide with appropriately substituted 4-amino-2-[(diethylamino)methyl]-6-alkylphenol dihydrochlorides. The latter precursors were prepared in a six-step synthesis starting from available 2-alkylphenols. Several of the title compounds display potent antimalarial activity in mice.

  DOI：

  10.1021/jm00388a027

文献信息

• Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold
  作者：Ion Niculescu-Duvaz、Esteban Roman、Steven R. Whittaker、Frank Friedlos、Ruth Kirk、Ian J. Scanlon、Lawrence C. Davies、Dan Niculescu-Duvaz、Richard Marais、Caroline J. Springer

  DOI：10.1021/jm070776b

  日期：2008.6.1

  developing inhibitors of mutant (V600E)BRAF. We have already reported on the optimization of the trimethoxyphenylamino moiety of 1. In this paper, we describe the synthesis of a series of compounds derived from 1 with the purpose of optimization of the pyrazine central core and the phenylacetamido moiety in order to increase the potency against (V600E)BRAF compared to CRAF. The biological activity of the new

  BRAF是一种丝氨酸/苏氨酸激酶，在某些类型的癌症（尤其是黑色素瘤）的发生中起关键作用。从23000的库的高通量筛选中，将2-（3,4,5-三甲氧基苯基氨基）-6-（3-乙酰氨基苯基）-吡嗪确定为低微摩尔（IC 50 = 3.5 microM）BRAF抑制剂化合物。选择该化合物作为开发突变体（V600E）BRAF抑制剂的程序的起点。我们已经报道了1的三甲氧基苯基氨基部分的优化。在本文中，我们描述了一系列衍生自1的化合物的合成，目的是优化吡嗪中心核和苯基乙酰胺基部分，以提高效力。针对（V600E）BRAF与CRAF的比较。在体外评估了新抑制剂对突变型（V600E）BRAF的生物学活性。鉴定出几种化合物，其（V600E）BRAF的IC 50为300-500 nM，所有评估的化合物与CRAF相比，对（V600E）BRAF的选择性高5-> 86倍。
• Facile Synthesis of 2H-Benzo[h]Chromenes via an Arylamine-Catalyzed Mannich Cyclization Cascade Reaction
  作者：Yueteng Zhang、Peng Ji、Xiang Meng、Feng Gao、Fanxun Zeng、Wei Wang

  DOI：10.3390/molecules26123617

  日期：——

  Mannich-cyclization cascade reaction was developed for facile synthesis of substituted 2H-benzo[h]chromenes. The notable feature of the process included the efficient generation of ortho-quinone methides (o-QMs) catalyzed by a simple aniline. The mild reaction conditions allowed for a broad spectrum of 1- and 2-naphthols and trans-cinnamaldehydes to engage in the cascade sequence with high efficiency.

  开发了一种简单的芳胺催化曼尼希环化级联反应，用于轻松合成取代的 2 H-苯并[ h ]色烯。该过程的显着特点包括在简单的苯胺催化下有效生成邻醌甲基化物（ o -QM）。温和的反应条件允许广谱的1-和2-萘酚以及反式肉桂醛高效地参与级联序列。
• Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds
  申请人：Springer Joy Caroline

  公开号：US20080015191A1

  公开（公告）日：2008-01-17

  The present invention pertains to certain pyrazines and pyridines, and derivatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently —N═ or —CH═; one of R P2 and R P3 is independently a group of the formula -J 1 -L 1 -Z; wherein: if Q is —N═, then -J 1 -L 1 -Z is independently: —NH-Z; —O-Z; or S-Z; if Q is —CH═, then -J 1 -L 1 -Z is independently: —NH—(CH 2 ) n -Z, wherein n is independently 0 or 1; —O-Z; or —S-Z; Z is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P2 and R P3 is independently —H, —NHR N1 , or —NHC(═O)R N2 ; wherein: R N1 , if present, is independently —H or aliphatic saturated C 1-4 alkyl; R N2 , if present, is independently —H or aliphatic saturated C 1-4 alkyl; one of R P5 and R P6 is independently a group of the formula —W—Y; wherein: W is independently: a covalent bond; —NR N4 —, —O—, —S—, —C(═O)—, —CH 2 —; —NR N4 —CH 2 —, —O—CH 2 —, —S—CH 2 —, —C(═O)—CH 2 —, —(CH 2 ) 2 —; —CH 2 —NR N4 —, —CH 2 —O—, —CH 2 —S—, or —CH 2 —C(═O)—; wherein R N4 , if present, is independently —H or aliphatic saturated C 1-4 alkyl; Y is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P5 and R P6 is independently —H; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, e.g., both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及某些吡嗪和吡啶以及它们的衍生物，其中，它们在抑制RAF（例如B-RAF）活性、抑制细胞增殖、治疗癌症等方面发挥作用，更具体地涉及以下式的化合物：（I）其中：Q独立地为—N═或—CH═；RP2和RP3中的一个独立地为以下式的基团-J1-L1-Z；其中：如果Q为—N═，则-J1-L1-Z独立地为：—NH-Z；—O-Z；或S-Z；如果Q为—CH═，则-J1-L1-Z独立地为：—NH—（CH2）n-Z，其中n独立地为0或1；—O-Z；或—S-Z；Z独立地为：C6-14碳芳基，C5-14杂芳基，C3-12碳环烷基，C3-12杂环烷基；并且独立地未取代或取代；RP2和RP3中的另一个独立地为—H，—NHRN1或—NHC(═O)RN2；其中：如果存在RN1，则独立地为—H或脂肪饱和的C1-4烷基；如果存在RN2，则独立地为—H或脂肪饱和的C1-4烷基；RP5和RP6中的一个独立地为以下式的基团—W—Y；其中：W独立地为：共价键；—NRN4—，—O—，—S—，—C(═O)—，—CH2—；—NRN4—CH2—，—O—CH2—，—S—CH2—，—C(═O)—CH2—，—(CH2)2—；—CH2—NRN4—，—CH2—O—，—CH2—S—，或—CH2—C(═O)—；其中如果存在RN4，则独立地为—H或脂肪饱和的C1-4烷基；Y独立地为：C6-14碳芳基，C5-14杂芳基，C3-12碳环烷基，C3-12杂环烷基；并且独立地未取代或取代；RP5和RP6中的另一个独立地为—H；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、N-氧化物、化学保护形式和前药。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，例如在体内和体外，来抑制RAF（例如B-RAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗因RAF、RTK等的抑制而得到改善的疾病和病况，如癌症（例如结直肠癌、黑色素瘤）等增生性疾病。
• Introduction of a Hydroxy Group at the Para Position and <i>N</i>-Iodophenylation of <i>N</i>-Arylamides Using Phenyliodine(III) Bis(Trifluoroacetate)
  作者：Naoki Itoh、Takeshi Sakamoto、Etsuko Miyazawa、Yasuo Kikugawa

  DOI：10.1021/jo0260847

  日期：2002.10.1

  The reaction of anilides with phenyliodine(III) bis(trifluoroacetate) (PIFA) in trifluoroacetic acid (TFA), TFA-CHCl3, or hexafluoroisopropyl alcohol (HFIP) is described. When the acyl group of the anilide is highly electronegative, such as trifluoroacetyl, or the phenyl group is substituted with an electron-withdrawing group, the 4-iodophenyl group is transferred from PIFA to the amide nitrogen to

  描述了在三氟乙酸（TFA），TFA-CHCl3或六氟异丙醇（HFIP）中，苯甲酸酯与苯基碘（III）双（三氟乙酸酯）（PIFA）的反应。当苯胺的酰基具有高负电性时，例如三氟乙酰基，或者苯基被吸电子基团取代，则4-碘苯基从PIFA转移到酰胺氮上，得到乙酰基二芳基胺。另一方面，当酰基具有诸如4-甲氧基苯基之类的供电子功能时，或者苯基被供电子性基团取代时，三氟乙酰氧基被转移至苯胺芳环的对位。该组在后处理过程中水解产生相应的苯酚。
• The solvolysis of N-acetoxy-1-N-acetylaminonaphthalene and N-acetoxy-2-N-acetylaminonaphthalene: divergent chemistry and mutagenic activity
  作者：Graham R. Underwood、Catherine M. Davidson

  DOI：10.1039/c39850000555

  日期：——

  Upon solvolysis in neutral 40% aqueous acetone, N-acetoxy-1-N- and N-acetoxy-2-N-acetylaminonaphthalene exhibit completely different modes of reaction; the former reacts with nitrenium ion formation, while the latter undergoes acyl oxygen scission.

  在中性的40％丙酮水溶液中溶剂化时，N-乙酰氧基-1- N-和N-乙酰氧基-2- N-乙酰氨基萘显示完全不同的反应方式。前者与氮离子形成反应，而后者经历酰基氧分裂。